keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C genotype 3

keyword
https://www.readbyqxmd.com/read/28644739/treatment-of-hepatitis-c-with-new-fixed-dose-combinations
#1
Vicente Soriano
The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%. However, a subset of patients remains at higher risk for treatment failure, including those infected with: i) genotype 3 and cirrhosis; ii) resistance-associated substitutions (RAS) occurring either as natural polymorphisms or selected after prior DAA failure; and iii) poor drug adherence associated with social disabilities (homeless, psychiatric illnesses, injection drug use, alcoholism, etc...
June 23, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28642869/detection-of-microrna-in-hepatic-cirrhosis-and-hepatocellular-carcinoma-in-hepatitis-c-genotype-4-in-egyptian-patients
#2
Hala M Demerdash, Hend M Hussien, Ehab Hassouna, Emad A Arida
BACKGROUND: In Egypt, the prevalence of chronic hepatitis C (CHC) infection is 13.8% of whole population and about 80% of the patients with hepatocellular carcinoma have underling hepatitis C. AIM: This study was designed to assess the diagnostic value of plasma miR-122 and miR-21 in patients with CHC, genotype-4, to detect fibrosis progression versus noninvasive indices and their diagnostic value in detection of early stages of hepatocellular carcinoma (HCC). METHODOLOGY: A prospective study that included 180 patients, divided into 3 groups: healthy controls (group I), CHC patients (group II), and hepatitis C patients with HCC (group III); all cases were subjected to thorough clinical, radiological, and laboratory investigations...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28641865/influence-of-baseline-meld-score-in-the-efficacy-of-treatment-of-hepatitis-c-with-simeprevir-and-sofosbuvir
#3
José María Moreno-Planas, Juan Ramón Larrubia-Marfil, Juan José Sánchez-Ruano, Julia Morillas-Ariño, Roberto Patón-Arenas, Rosa María Sáiz-Chumillas, Emilia Tébar-Romero, Alfredo Lucendo-Villarín, Pilar Gancedo-Bringas, Mario Solera-Muñoz, María Del Mar Vicente-Gutiérrez, Elisa Martínez-Alfaro
INTRODUCTION: There are few published studies on predictors of response to treatment with sofosbuvir and simeprevir in HCV patients. OBJECTIVE: The objective of the study was to analyse possible predictors of response to simeprevir (SMV) and sofosbuvir (SOF) in patients infected with hepatitis C genotypes 1 or 4. PATIENTS AND METHODS: Prospective observational cohort study in 12 hospitals. The primary efficacy endpoint was SVR rate 12 weeks after end of treatment (SVR12)...
June 19, 2017: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/28636638/outcomes-from-a-large-10-year-hepatitis-c-treatment-programme-in-people-who-inject-drugs-no-effect-of-recent-or-former-injecting-drug-use-on-treatment-adherence-or-therapeutic-response
#4
Omar Elsherif, Ciaran Bannan, Shay Keating, Susan McKiernan, Colm Bergin, Suzanne Norris
BACKGROUND AND AIMS: People who inject drugs (PWID) are historically viewed as having "difficult to treat" hepatitis C disease, with perceived inferior treatment adherence and outcomes, and concerns regarding reinfection risk. We evaluated for differences in treatment adherence and response to Peginterferon-alfa-2a/Ribavirin (Peg-IFNα/RBV) in a large urban cohort with and without a history of remote or recent injection drug use. METHODS: Patient data was retrospectively reviewed for 1000 consecutive patients-608 former (no injecting drug use for 6 months of therapy), 85 recent (injecting drug use within 6 months) PWID, and 307 non-drug users who were treated for chronic hepatitis C with Peg-IFNα/RBV...
2017: PloS One
https://www.readbyqxmd.com/read/28635613/association-of-the-s267f-variant-on-ntcp-gene-and-treatment-response-to-pegylated-interferon-in-patients-with-chronic-hepatitis-b-a-multicentre-study
#5
Kessarin Thanapirom, Sirinporn Suksawatamnuay, Wattana Sukeepaisarnjaroen, Sombat Treeprasertsuk, Tawesak Tanwandee, Phunchai Charatcharoenwitthaya, Satawat Thongsawat, Apinya Leerapun, Teerha Piratvisuth, Rattana Boonsirichan, Chalermrat Bunchorntavakul, Chaowalit Pattanasirigool, Bubpha Pornthisarn, Supoj Tuntipanichteerakul, Ekawee Sripariwuth, Woramon Jeamsripong, Teeranan Sanpanjit, Yong Poovorawan, Piyawat Komolmit
BACKGROUND: Sodium taurocholate co-transporting polypeptide (NTCP) is a cell receptor for hepatitis B virus (HBV). The S267F variant on the NTCP gene is inversely associated with the chronicity of HBV infection, progression to cirrhosis and hepatocellular carcinoma in East Asian populations. This aim of this study was to determine whether the S267F variant was associated with response to pegylated interferon (Peg-IFN) in patients with chronic HBV infection. METHODS: Two hundred and fifty-seven patients with chronic HBV, treated with Peg-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL)...
June 21, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28634687/noninvasive-serum-models-to-predict-significant-liver-related-events-in-chronic-hepatitis-c
#6
Ragesh Babu Thandassery, Saad Al Kaabi, Madiha E Soofi, Benjamin Tharian, Rajvir Singh
AIM: We aim to compare 20 noninvasive fibrosis scores (NIFS), derived from routine blood tests, for predicting significant liver-related adverse events (SLRE) in patients with chronic hepatitis C (CHC) after anti-viral treatment (AVT) with the goal to identify independent predictors for these outcomes. METHODS: From 1605 patients who received AVT (pegylated interferon and ribavirin) from January 2002 to June 2014, 20 NIFS were calculated from routine blood tests prior to AVT...
June 20, 2017: Hepatology International
https://www.readbyqxmd.com/read/28633998/changes-in-risk-behaviours-during-and-following-treatment-for-hepatitis-c-virus-infection-among-people-who-inject-drugs-the-activate-study
#7
Håvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, Brian Conway, Markus Backmund, Philip Bruggmann, Julie Bruneau, Stefan Bourgeois, Adrian Dunlop, Graham R Foster, Margaret Hellard, Geert Robaeys, Maria C Thurnheer, Martin Weltman, Janaki Amin, Philippa S Marks, Sophie Quiene, Gregory J Dore, Olav Dalgard, Jason Grebely
BACKGROUND: The risk of hepatitis C virus (HCV) reinfection due to continued injecting risk behaviours might remain a barrier to HCV treatment among people who inject drugs. We aimed to evaluate changes in risk behaviours during and following HCV treatment among people with ongoing injecting drug use or receiving opioid substitution treatment (OST). METHODS: ACTIVATE was an international multicentre clinical trial conducted between 2012 and 2014. Participants with HCV genotypes 2/3 infection were treated with peg-interferon/ribavirin for 12 or 24 weeks and completed a self-administered behavioural questionnaire at each study visit...
June 17, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28631602/nationwide-overview-of-the-distribution-of-hepatitis-b-virus-genotypes-in-brazil-a-1000-sample-multicentre-study
#8
Elisabeth Lampe, Francisco C A Mello, Marcia P do Espírito-Santo, Cintia M C Oliveira, Dennis A Bertolini, Neiva S L Gonçales, Regina C Moreira, Carlos A S Fernandes, Haydée C L Nascimento, Rejane M T Grotto, Maria Inês M C Pardini, On Behalf Of The Brazilian Hepatitis B Research Group
The influence of hepatitis B virus (HBV) genotypes in the natural history of the disease and its response to antiviral treatment have been addressed in many studies. In Brazil, studies on HBV genotype circulation have been restricted to specific population groups and states. Here, we have conducted a nationwide multicentre study with an unprecedented sample size representing all Brazilian regions in an effort to better understand the viral variants of HBV circulating among chronic carriers. Seven HBV genotypes were found circulating in Brazil...
June 20, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28624134/efficacy-of-response-guided-directly-observed-pegylated-interferon-and-self-administered-ribavirin-for-people-who-inject-drugs-with-hepatitis-c-virus-genotype-2-3-infection-the-activate-study
#9
Jason Grebely, Olav Dalgard, Evan B Cunningham, Behzad Hajarizadeh, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Janaki Amin, Philippa S Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Margaret Hellard, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Cornelia Staehelin, Gregory J Dore
BACKGROUND: There are few data on treatment for hepatitis C virus (HCV) infection among people with ongoing injecting drug use. This study evaluated the efficacy of response-guided therapy for chronic HCV genotypes 2/3 infection among people with ongoing injecting drug use or receiving opioid substitution therapy (OST). A secondary aim was to identify predictors of HCV treatment response. METHODS: ACTIVATE was a multicentre clinical trial recruited between 2012 and 2014...
June 14, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28618285/belgian-experience-with-direct-acting-antivirals-in-people-who-inject-drugs
#10
Rob Bielen, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixko, Jochen Decaestecker, Chantal De Galocsy, Filip Janssens, Mike Cool, Lode Van Overbeke, Christophe Van Steenkiste, François D'heygere, Wilfried Cools, Frederik Nevens, Geert Robaeys
BACKGROUND AND AIM: Hepatitis C viral infection (HCV) has become a curable disease due to the development of direct acting antivirals (DAA). The WHO has set a target to eliminate HCV completely. Therefore, people who inject drugs (PWID) also need to be treated. In this study, we compared the real-life uptake and outcome of DAA treatment for HCV in PWID and non-PWID. METHODS: We performed a nation-wide, retrospective cohort study in 15 hospitals. All patients who were treated with simeprevir-sofosbuvir, daclatasvir-sofosbuvir, or ombitasvir/paritaprevir ritonavir-dasabuvir between December 2013 and November 2015 were included...
May 30, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28615203/phosphorylation-of-serine-225-in-hepatitis-c-virus-ns5a-regulates-protein-protein-interactions
#11
Niluka Goonawardane, Anna Gebhardt, Christopher Bartlett, Andreas Pichlmair, Mark Harris
Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a phosphoprotein that plays key, yet poorly defined, roles in both virus genome replication and virion assembly/release. It has been proposed that differential phosphorylation could act as a switch to regulate the various functions of NS5A, however the mechanistic details of the role of this post-translational modification in the virus life cycle remains obscure. We previously reported (Ross-Thriepland et al, 2015) a role for phosphorylation at serine 225 (S225) of NS5A in the regulation of JFH-1 (genotype 2a) genome replication...
June 14, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28612194/clinical-and-pathological-risk-factors-associated-with-liver-fibrosis-and-steatosis-in-african-americans-with-chronic-hepatitis-c
#12
Ali Afsari, Edward Lee, Babak Shokrani, Tina Boortalary, Zaki A Sherif, Mehdi Nouraie, Adeyinka O Laiyemo, Kawtar Alkhalloufi, Hassan Brim, Hassan Ashktorab
BACKGROUND AND AIM: Several factors involved in the development of liver fibrosis in African-American patients with chronic hepatitis C have not been well studied. We aimed to evaluate some of these risk factors. METHODS: We reviewed pathology and medical records of 603 African-Americans with chronic hepatitis C virus (HCV) infection at Howard University Hospital from January 2004 to December 2013. Among the clinical and pathological data collected were HIV (human immunodeficiency virus), HCV genotype, hepatitis B virus (HBV), diabetes mellitus (DM), hypertension (HTN), body mass index (BMI), and hepatic steatosis...
June 13, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28610605/adherence-to-response-guided-pegylated-interferon-and-ribavirin-for-people-who-inject-drugs-with-hepatitis-c-virus-genotype-2-3-infection-the-activate-study
#13
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore, Jason Grebely
BACKGROUND: The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. METHODS: ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4)...
June 13, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28608973/high-hepatitis-c-cure-rates-among-black-and-non-black-hiv-infected-adults-in-an-urban-center
#14
Oluwaseun Falade-Nwulia, Catherine Sutcliffe, Juhi Moon, Geetanjali Chander, Tanyaporn Wansom, Jeanne Keruly, Jennifer Katzianer, Amy Nathanson, Jillian Marks, Shruti Mehta, David Thomas, Richard Moore, Mark Sulkowski
Background Hepatitis C virus (HCV) cure rates have been similar in patients with and without HIV co-infection; however, in the ION-4 study, black patients treated with ledipasvir/sofosbuvir were significantly less likely to achieve cure (90%) compared to non-black patients (99%). There are limited real world data on the effectiveness of oral direct acting antivirals (DAAs) in predominantly minority HIV/HCV co-infected populations. Methods We analyzed HCV treatment outcomes among 255 HCV co-infected patients initiating DAAs between February 2014 and March 2016 in an urban clinic in Baltimore, Maryland...
June 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28608619/efficacy-and-safety-of-daclatasvir-based-antiviral-therapy-in-hcv-recurrence-after-liver-transplantation-role-of-cirrhosis-and-genotype-3-a-multi-centre-cohort-study
#15
Magdalena Salcedo, Martín Prieto, Lluís Castells, Juan Manuel Pascasio, Jose Luis Montero Alvarez, Inmaculada Fernández, Gloria Sánchez-Antolín, Luisa González-Diéguez, Miguel García-Gonzalez, Alejandra Otero, Sara Lorente, Maria Dolores Espinosa, Milagros Testillano, Antonio González, Jose Castellote, Fernando Casafont, Maria-Carlota Londoño, Jose Antonio Pons, Esther Molina Pérez, Valentín Cuervas-Mons, Sonia Pascual, Jose Ignacio Herrero, Isidoro Narváez, Carmen Vinaixa, Jordi Llaneras, Jose Manuel Sousa, Rafael Bañares
BACKGROUND & AIMS: Direct-acting antiviral agents (DAA) combining daclatasvir (DCV) have reported good outcomes in the recurrence of hepatitis C virus (HCV) infection after liver transplant (LT). However, its effect on the severe recurrence and the risk of death remains controversial. We evaluated the efficacy, predictors of survival, and safety of DAC-based regimens in a large real-world cohort. METHODS: A total of 331 patients received DCV-based therapy. Duration of therapy and ribavirin use were at the investigator's discretion...
June 13, 2017: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/28603097/circulating-autoantibodies-to-endogenous-erythropoietin-are-associated-with-chronic-hepatitis-c-virus-infection-related-anemia
#16
Aristotelis Tsiakalos, Theoharis Voumvas, Alexandros Psarris, Christina K Oikonomou, Dimitrios C Ziogas, Ioannis Ketikoglou, Grigorios Hatzis, Nikolaos V Sipsas
BACKGROUND: Chronic hepatitis C virus (HCV) infection is associated with autoimmune phenomena and is often complicated by anemia. Circulating autoantibodies to endogenous erythropoietin (anti-EPO) have been detected in patients with chronic viral infections and were correlated to anemia. The present study aimed to determine anti-EPO prevalence in patients with chronic HCV infection and investigate its possible association with anemia. METHODS: Ninety-three consecutive patients (62 males and 31 females) with chronic HCV infection, who had never received antiviral therapy or recombinant EPO, were enrolled in the study...
June 2017: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/28600703/prevalence-of-s-gene-mutations-within-the-major-hydrophilic-region-of-hepatitis-b-virus-in-patients-in-dongguan-southern-china
#17
Siping Li, Mingyu Xie, Wenrui Li, Qi Peng, Baimao Zhong, Xiaomei Lu, Qiang Ma
HBsAg point mutations within the major hydrophilic region (MHR) have frequently been reported to be associated with diagnostic failure, vaccine escape and immunotherapy escape. However, the prevalence of escape mutations in chronic hepatitis B (CHB) patients has not been systematically studied in patients from southern China within the past decade. This study aimed to determine the prevalence of escape mutations within the MHR of hepatitis B virus in patients in Dongguan, southern China. Between June 2015 and May 2016, 391 patients who were chronically infected with HBV were enrolled in the study, including 240 patients with the genotype B strain and 151 with the genotype C strain...
June 9, 2017: Archives of Virology
https://www.readbyqxmd.com/read/28599618/hiv-coinfected-patients-respond-worse-to-direct-acting-antiviral-based-therapy-against-chronic-hepatitis-c-in-real-life-than-hcv-monoinfected-individuals-a-prospective-cohort-study
#18
Karin Neukam, Luis E Morano-Amado, Antonio Rivero-Juárez, María Mancebo, Rafael Granados, Francisco Téllez, Antonio Collado, María J Ríos, Ignacio de Los Santos-Gil, Sergio Reus-Bañuls, Francisco Vera-Méndez, Paloma Geijo-Martínez, Marta Montero-Alonso, Marta Suárez-Santamaría, Juan A Pineda
OBJECTIVE: HIV/HCV-coinfected patients and hepatitis C virus (HCV) monoinfected subjects are thought to respond equally to direct-acting antiviral (DAA)-based therapy despite the lack of data derived from clinical trials. This study is aimed to evaluate the impact of HIV coinfection on the response to DAA-based treatment against HCV infection in the clinical practice. PATIENTS AND METHODS: In a prospective multicohort study, patients who initiated DAA-based therapy at the Infectious Disease Units of 33 hospitals throughout Spain were included...
May 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28598093/-genotype-distribution-of-1-998-strains-of-hepatitis-c-virus-in-west-china-hospital-of-sichuan-university-from-2009-to-2013
#19
Gui-Rong Xiao, Ting Xu
OBJECTIVES: To investigate hepatitis C virus (HCV) genotype distribution detected in West China Hospital of Sichuan University. METHODS: We analyzed genotype distribution data on HCV infected patients who had information of HCV genotypes from January 2009 to December 2013 diagnosed in West China Hospital of Sichuan University. RESULTS: Five genotypes and 15 genetic subtypes of HCV were found among the 1 998 cases, and 4 of the patients were infected with mixed HCV subtype...
September 2016: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28596225/increased-warfarin-requirements-in-a-patient-with-chronic-hepatitis-c-infection-receiving-sofosbuvir-and-ribavirin
#20
Daisy Peterson, Amy Van Ermen
PURPOSE: A case of increased warfarin requirements during treatment with sofosbuvir and ribavirin for chronic hepatitis C virus (HCV) infection is reported. SUMMARY: A 63-year-old white man receiving long-term anticoagulation with warfarin for atrial fibrillation and a history of cardioembolic stroke was initiated in September 2014 on a 12-week course of sofosbuvir 400 mg orally daily and weight-based ribavirin 600 mg orally twice daily for HCV genotype 2 infection...
June 15, 2017: American Journal of Health-system Pharmacy: AJHP
keyword
keyword
85439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"